Results 21 to 30 of about 3,726 (180)

A non-clinical comparative study of IL-23 antibodies in psoriasis

mAbs, 2021
Four antibodies that inhibit interleukin (IL)-23 are approved for the treatment of moderate-to-severe plaque psoriasis. Here, we present non-clinical data comparing ustekinumab, guselkumab, tildrakizumab and risankizumab with regard to thermostability ...
Li Zhou, Yibing Wang, Qi Wan, Fei Wu, Jeffrey Barbon, Robert Dunstan, Stephen Gauld, Mark Konrad, Laura Leys, Richard McCarthy, Marian Namovic, Christine Nelson, Gary Overmeyer, Denise Perron, Zhi Su, Leyu Wang, Susan Westmoreland, Jun Zhang, Rui Zhu, Geertruida Veldman   +19 more
doaj   +1 more source

Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study [version 2; peer review: 2 approved]

F1000Research, 2022
Background: Psoriasis is a chronic inflammatory disease which can impact quality of life. In the past decade multiple biologic treatments have been released with encouraging results. Guselkumab is a monoclonal antibody targeting IL-23p19.
Fiorella Vasquez Chinchay, Manuel Galán-Gutiérrez, Jose C. Armario-Hita, Amalia Pérez-Gil, Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire   +5 more
doaj   +1 more source

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis

Dermatology and Therapy, 2023
Introduction The aim of this study was to evaluate guselkumab efficacy on regional psoriasis in a subset of psoriasis patients with a self-reported psoriatic arthritis (PsA) diagnosis.
Ana-Maria Orbai, Soumya D. Chakravarty, Yin You, May Shawi, Ya-Wen Yang, Joseph F. Merola   +5 more
doaj   +1 more source

Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling

Frontiers in Immunology
IL-23 is implicated in the pathogenesis of immune-mediated inflammatory diseases, and myeloid cells that express Fc gamma receptor 1 (FcγRI or CD64) on their surface have been recently identified as a primary source of IL-23 in inflamed tissue.
Kacey L. Sachen, Deepa Hammaker, Indra Sarabia, Brian Stoveken, John Hartman, Kristin L. Leppard, Nicholas A. Manieri, Phuc Bao, Carrie Greving, Eilyn R. Lacy, Matthew DuPrie, Joshua Wertheimer, Janise D. Deming, Joseph Brown, Amy Hart, He (Hurley) Li, Tom C. Freeman, Brice Keyes, Kristen Kohler, Ian White, Nathan Karpowich, Ruth Steele, M. Merle Elloso, Steven Fakharzadeh, Kavitha Goyal, Frédéric Lavie, Maria T. Abreu, Matthieu Allez, Raja Atreya, Robert Bissonnette, Kilian Eyerich, Kilian Eyerich, James G. Krueger, Dennis McGonagle, Iain B. McInnes, Christopher Ritchlin, Anne M. Fourie   +36 more
doaj   +1 more source

Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis

Journal of Dermatological Treatment, 2023
Background Head-to-head comparisons through randomized controlled trials (RCTs) provide high-quality evidence to inform healthcare decisions. In their absence, indirect comparisons are often performed; however, evidence is limited on how valid matching ...
James Signorovitch, Joris Diels, Suzy Van Sanden, Agata Schubert, Fareen Hassan, Pushpike Thilakarathne, Bulent Ozturk, Norma Barthelmes, Kristian Reich   +8 more
doaj   +1 more source

Epithelial TRIM27 Inhibits Intestinal Inflammation in Ulcerative Colitis by the USP7/TRIM27‐IKK Double Negative‐Feedback

Advanced Science, EarlyView.
ABSTRACT The E3 ubiquitin ligase tripartite motif 27 (TRIM27) is a negative regulator of NF‐κB activation and the innate immune response, and TRIM27 deficiency significantly impairs dextran sulfate sodium (DSS)‐induced colitis. The function of TRIM27 in intestinal epithelial cells (IECs), the mechanism by which TRIM27 inhibits the NF‐κB pathway and its
Weimin Xu, Zhebin Hua, Zhujiang Dai, Shasha Zhang, Yihan Jiang, Wensong Ge, YingWei Chen, Zhongchuan Wang, Bing Zhang, Chen‐Ying Liu, Peng Du   +10 more
wiley   +1 more source

Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials

Rheumatology and Therapy
Introduction Two biologic therapies for psoriatic arthritis (PsA), guselkumab and ustekinumab, have demonstrated superior efficacy versus placebo in clinical trials.
Pushpike Thilakarathne, Agata Schubert, Steve Peterson, Wim Noel, Barkha P. Patel, Fareen Hassan   +5 more
doaj   +1 more source

Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy

JID Innovations
Background: Psoriasis is an immune-mediated inflammatory disease characterized by activation of IL-23–driven IL-17–producing T cell and other IL-23 receptor–positive IL-17–producing cell responses.
Andrew Blauvelt, Richard G. Langley, Patrick J. Branigan, Xuejun Liu, Yanqing Chen, Samuel DePrimo, Keying Ma, Brittney Scott, Kim Campbell, Ernesto J. Muñoz-Elías, Kim A. Papp   +10 more
doaj   +1 more source

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study

ACR Open Rheumatology, 2023
Objective To evaluate efficacy and safety of the interleukin‐23p19‐subunit inhibitor, guselkumab, in DISCOVER‐1 patients with active psoriatic arthritis (PsA) by prior use of tumor necrosis factor inhibitor (TNFi).
Christopher T. Ritchlin, Atul Deodhar, Wolf‐Henning Boehncke, Enrique R. Soriano, Alexa P. Kollmeier, Xie L. Xu, Federico Zazzetti, May Shawi, Yusang Jiang, Shihong Sheng, Philip S. Helliwell   +10 more
doaj   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source